Journal
ONCOLOGIST
Volume 16, Issue 4, Pages 388-403Publisher
WILEY
DOI: 10.1634/theoncologist.2010-0386
Keywords
-
Categories
Funding
- Janssen Pharmaceutical Companies of Johnson & Johnson in Europe, Middle East, and Africa (EMEA)
Ask authors/readers for more resources
The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. The Oncologist 2011;16:388-403
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available